WGS - genedx.com Projected Price to Earnings

Official company branding of GeneDx (WGS)

Business protection via AI algorithms and an exclusive mutation archive provides GeneDx Holdings Corp. (WGS) with resilience, supporting the issuer's expected P/E, which currently stands at 39.10. The valuation trajectory is driven by neonatologists' demand for genome sequencing. A leading position in rare pathology diagnostics and high test accuracy create significant barriers to entry for new market players.

genedx.com - WGS Future Price to Earnings Multiple (period 04/28/2023 - 11/17/2026)

Summary analytical data breakdowns for genedx.com (WGS)

- market capitalization statistics:
General company analysis:GeneDx Holdings Corp.
Signature product of GeneDx Holdings Corp.

To assess the credit quality of GeneDx Holdings Corp. (WGS), the analyst utilizes the company's forward P/E ratio dynamics, which compare current market value to expected annual earnings. High customer switching costs and a unique genetic dataset confirm business resilience; however, an increase in this indicator signals a diminishing margin of safety and a higher risk of price correction.

Who GeneDx Holdings Corp. competes with

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|RARE: Forward P/E Multiple|Beam Therapeutics Corp - Future Price to Earnings Multiple|Projected Price to Earnings SRPT|twistbioscience.com (TWST) - Market Cap to Projected Earnings|Forward P/E Multiple TXG|NTLA (Intellia) - Future Price to Earnings Multiple|Future Price to Earnings Stoke STOK|BioLife (BLFS) - Projected Price to Earnings Ratio|wavelifesciences.com - Forward P/E Multiple|Price to Expected Earnings Ratio MAZE|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|Projected Price to Earnings TSHA|QURE - Forward Price to Earnings Multiple|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple